Reported regimens containing alemtuzumab.
| Conditioning Regimen . | Reference . |
|---|---|
| Abbreviations: BEAM, BCNU, etoposide, Ara-C, melphalan; TBI, total body irradiation; ATG, antithymocyte globulin. | |
| Alemtuzumab 100 mg + fludarabine 150 mg/m2 + melphalan 140 mg/m2 | 5 |
| Alemtuzumab 100 mg + fludarabine 150 mg/m2 + busulfan 8 mg/kg | 6 |
| Campath-1G 50 mg + BEAM | 7 |
| Alemtuzumab 100 mg + 2 Gy TBI | 8 |
| Fludarabine 180 mg/m2 + ATG 40 mg/kg + busulfan 6.4 mg/kg + in vitro T-cell depletion with alemtuzumab 20 mg | 9 |
| TBI 450 cGy + fludarabine 120 mg/m2 + alemtuzumab 40 mg | 10 |
| Alemtuzumab 100 mg + fludarabine 120 mg/m2 + cyclophosphamide 2 g/m2 + in vitro T-cell depletion with alemtuzumab | 11 |
| Conditioning Regimen . | Reference . |
|---|---|
| Abbreviations: BEAM, BCNU, etoposide, Ara-C, melphalan; TBI, total body irradiation; ATG, antithymocyte globulin. | |
| Alemtuzumab 100 mg + fludarabine 150 mg/m2 + melphalan 140 mg/m2 | 5 |
| Alemtuzumab 100 mg + fludarabine 150 mg/m2 + busulfan 8 mg/kg | 6 |
| Campath-1G 50 mg + BEAM | 7 |
| Alemtuzumab 100 mg + 2 Gy TBI | 8 |
| Fludarabine 180 mg/m2 + ATG 40 mg/kg + busulfan 6.4 mg/kg + in vitro T-cell depletion with alemtuzumab 20 mg | 9 |
| TBI 450 cGy + fludarabine 120 mg/m2 + alemtuzumab 40 mg | 10 |
| Alemtuzumab 100 mg + fludarabine 120 mg/m2 + cyclophosphamide 2 g/m2 + in vitro T-cell depletion with alemtuzumab | 11 |